  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  
 
 
 
A single -center registry and embedded interventional  study of the effects of 
COVID -19 with and without  treatment with AT-001 on cardiac structure and 
function in patients hospi[INVESTIGATOR_125735] -19 infection  
 
Principal Investigator:  
 [INVESTIGATOR_125736], MD  
Additional  Investigator s: 
 See table below  
NYULMC Study Number:  s20-[ZIP_CODE]  
Funding Sponsor:  Applied Therapeutics, Inc.  
[ADDRESS_141427] [LOCATION_001], NY [ZIP_CODE] [PHONE_2827]  
www.appliedtherapeutics.com  
IND/IDE Number:  IND number [ADDRESS_141428]:  AT-[ADDRESS_141429] Provider:  Applied Therapeutics, Inc.  
[ADDRESS_141430] [LOCATION_001], NY [ZIP_CODE] [PHONE_2827]  
www.appliedtherapeutics.com  
ClinicalTrials.gov Number                 [STUDY_ID_REMOVED]  
 
Protocol  Revision History:  
 
Version Number  Version Date  Summary of Revisions Made  
1.0 22 MARCH 
2020  Initial Draft  
1.1 24 MARCH 
2020  Updated With AT -001 intervention  
1.2 26 MARCH 
2020  Revisions to study procedures  
1.3 13 APRIL 2020  Addition of NYU Winthrop for AT001 intervention  
1.4 03 MAY 2020  Revisions to entry criteria and analysis related to co -
enrollment and EUA of remdesivir  
 
Study number:  s20-[ZIP_CODE]   Page ii 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019   
Statement of Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable 
US government research regulations, and institutional research policies and procedures. The International 
Conference on Harmonisation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (s ometimes 
referred to as “ICH -GCP” or “E6”) will be applied only to the extent that it is compatible with FDA and 
DHHS regulations.  The Principal Investigator [INVESTIGATOR_7433], or changes to the 
protocol will take place without prior agree ment from the sponsor and documented approval from the 
Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial 
participants. All personnel involved in the conduct of this study have completed Human Subjects  
Protection Training.  
  
Study number:  s20-[ZIP_CODE]   Page iii 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_141431] OF ABBREVIATIONS  ................................ ................................ ................................ ........................  VI 
PROTOCOL SUMMARY  ................................ ................................ ................................ ...............................  1 
SCHEMATIC OF STUDY DESIGN  ................................ ................................ ................................ ...............  4 
1 KEY ROLES  ................................ ................................ ................................ ................................ ..........  5 
2 , BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ................................ ...................  5 
2.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ................................ ................................  5 
2.2 NAME [CONTACT_33914]  ................................ ...............................  7 
2.2.1  Preclinical Data  ................................ ................................ ................................ ........................  7 
2.2.2  Clinical Data to Date  ................................ ................................ ................................ ................  8 
2.2.3  Dose R ationale (if applicable)  ................................ ................................ ................................ .. 9 
2.3 RATIONALE  ................................ ................................ ................................ ................................ ..... 9 
2.4 POTENTIAL RISKS & BENEFITS  ................................ ................................ ................................ ........  9 
2.4.1  Known Potential Risks  ................................ ................................ ................................ .............  9 
2.4.2  Known Potential Benefits  ................................ ................................ ................................ ....... 10 
3 OBJECTIVES AND PURPOSE  ................................ ................................ ................................ ..........  10 
3.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ .....................  10 
3.2 SECONDARY OBJECTIVES (IF APPLICABLE ) ................................ ................................ .....................  10 
4 STUDY DESIGN AND ENDPOINTS  ................................ ................................ ................................ .. 10 
4.1 DESCRIPTION OF STUDY DESIGN  ................................ ................................ ................................ ... 10 
4.2 STUDY ENDPOINTS  ................................ ................................ ................................ .......................  11 
4.2.1  Primary Study Endpoints ................................ ................................ ................................ ........  11 
4.2.2  Secondary Endpoints  ................................ ................................ ................................ .............  11 
5 STUDY ENROLLMENT AND WITHDRAWAL  ................................ ................................ ...................  11 
5.1 INCLUSION CRITERIA  ................................ ................................ ................................ .....................  11 
5.2 EXCLUSION CRITERIA  ................................ ................................ ................................ ....................  12 
5.3 VULNERABLE SUBJECTS  ................................ ................................ ................................ ................  12 
5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  ................................ ................................ ..........  13 
5.4.1  Use of DataCore/Epic Information for Recruitment Purposes  ................................ ...............  13 
5.5 DURATION OF STUDY PARTICIPATION  ................................ ................................ .............................  13 
5.6 TOTAL NUMBER OF PARTICIPANTS AND SITES ................................ ................................ ................  13 
5.7 PARTICIPANT WITHDRAWAL OR TERMINATION  ................................ ................................ ................  13 
5.7.1  Reasons for Withdrawal or Termination  ................................ ................................ ................  13 
5.7.2  Handling of Participant Withdrawals or Termination  ................................ ..............................  14 
5.8 PREMATURE TERMINATION OR SUSPENSION OF STUDY  ................................ ................................ .. 14 
6 STUD Y AGENT (STUDY DRUG, DEVICE, BIOLOGIC, VACCINE ETC.) AND/OR PROCEDURAL 
INTERVENTION  ................................ ................................ ................................ ................................ ..........  14 
6.1 STUDY AGENT (S) AND CONTROL DESCRIPTION  ................................ ................................ ..............  [ADDRESS_141432] Storage and Stability  ................................ ................................ ................................  15 
6.1.4  Preparation  ................................ ................................ ................................ .............................  15 
6.1.5  Dosing and Administration  ................................ ................................ ................................ ..... 15 
6.1.6  Route of Administr ation  ................................ ................................ ................................ ..........  15 
6.1.7  Duration of Therapy  ................................ ................................ ................................ ...............  15 
6.1.8  Tracking of Dose  ................................ ................................ ................................ ....................  15 
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  ................................ ................................ ..............  15 
Study number:  s20-[ZIP_CODE]   Page iv 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  7 STUDY PROCEDURES AND SCHEDULE  ................................ ................................ ........................  15 
7.1 STUDY PROCEDURES /EVALUATIONS  ................................ ................................ ..............................  [ADDRESS_141433] of Care Study Procedures  ................................ ................................ ......................  16 
7.2 LABORATORY PROCEDURES /EVALUATIONS  ................................ ................................ ....................  16 
7.2.1  Clinical Laboratory Eval uations  ................................ ................................ ..............................  16 
7.3 STUDY SCHEDULE  ................................ ................................ ................................ ........................  16 
7.3.1  Enrollment/Baseline  ................................ ................................ ................................ ...............  16 
7.3.2  Daily Interventional Study Visits (up to 14 days)  ................................ ................................ ... 16 
7.3.3  Final Study Visit  ................................ ................................ ................................ .....................  17 
7.3.4  Withdrawal/Early Termination Visit  ................................ ................................ ........................  17 
7.4 CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ....................  17 
7.4.1  Precautionary Medications, Treatments, and Procedures  ................................ .....................  17 
7.5 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ........................  17 
7.6 PROPHYLA CTIC MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ...................  17 
7.7 RESCUE MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ..............................  17 
7.8 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE ................................ .........................  17 
8 ASSESSMENT OF SAFETY  ................................ ................................ ................................ ..............  17 
8.1 SPECIFICATION OF SAFETY PARAMETERS  ................................ ................................ ......................  17 
8.1.1  Definition of Adverse Events (AE) ................................ ................................ ..........................  17 
8.1.2  Definition of Serious Adverse Events (SAE)  ................................ ................................ ..........  18 
8.1.3  Definition of Unanticipated Problems (UP)  ................................ ................................ ............  18 
8.2 CLASSIFICATION O F AN ADVERSE EVENT ................................ ................................ ........................  19 
8.2.1  Severity of Event  ................................ ................................ ................................ ....................  19 
8.2.2  Relationship to Study Agent  ................................ ................................ ................................ ... 19 
8.2.3  Expectedness  ................................ ................................ ................................ .........................  19 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP ................................ .... 19 
8.4 REPORTING PROCEDURES – NOTIFYING THE IRB ................................ ................................ ...........  20 
8.4.1  Adverse Event Reporting  ................................ ................................ ................................ ....... 20 
8.4.2  Serious Adverse Event Reporting  ................................ ................................ ..........................  20 
8.4.3  Unanticipated Problem Reporting  ................................ ................................ ..........................  21 
8.4.4  Reporting of Pregnancy  ................................ ................................ ................................ .........  21 
8.5 REPORTING PROCEDURES – NOTIFYING THE STUDY SPONSOR  ................................ .......................  22 
8.6 STUDY HALTING RULES................................ ................................ ................................ .................  22 
8.7 SAFETY OVERSIGHT  ................................ ................................ ................................ ......................  22 
9 CLINICAL MONITORING  ................................ ................................ ................................ ...................  23 
10 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ... 23 
10.1 STATISTICAL AND ANALYTICAL PLANS (SAP)  ................................ ................................ ..................  23 
10.2 STATISTICAL HYPOTHESES  ................................ ................................ ................................ ............  23 
10.3 ANALYSIS DATASETS ................................ ................................ ................................ .....................  23 
10.4 DESCRIPTION OF STATISTICAL METHODS  ................................ ................................ .......................  23 
10.4.1  General Approach  ................................ ................................ ................................ ..............  23 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  ................................ ................................ ..... 23 
10.4.3  Analysis of the Secondary Endpoint(s) ................................ ................................ ..............  24 
10.4.4  Safety Analyses  ................................ ................................ ................................ .................  24 
10.4.5  Adherence and Retention Analyses  ................................ ................................ ..................  24 
10.4.6  Baseline Descriptive Statistics  ................................ ................................ ...........................  24 
10.5 SAMPLE SIZE ................................ ................................ ................................ ................................  24 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................ . 24 
12 QUALITY ASSURANCE AND QUALITY CONTROL  ................................ ................................ ........  25 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................ ................................ .............  [ADDRESS_141434]  ................................ ................................ ................................ ......................  25 
Study number:  s20-[ZIP_CODE]   Page v 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_141435]  ................................ ................................ ................................ ..... 26 
13.3 INFORMED CONSENT PROCESS  ................................ ................................ ................................ ..... 26 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  ...............  [ADDRESS_141436] POLICY  ................................ ................................ ................................ ... 30 
18 REFERENCES  ................................ ................................ ................................ ................................ .... 31 
19 ATTACHMENTS  ................................ ................................ ................................ ................................ . 32 
20 SCHEDULE OF EVENTS  ................................ ................................ ................................ ...................  33 
 
 
  
Study number:  s20-[ZIP_CODE]   Page vi 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_141437] of Abbreviations  
 
AE Adverse Event/Adverse Experience  
ARDS  Adult Respi[INVESTIGATOR_125737] -[ADDRESS_141438]  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_33891])  
OHRP  Office for Human Research Protections  
OHSR  Office of Human Subjects Research  
PI [INVESTIGATOR_125738]/Serious Adverse Experience  
SARS -CoV -[ADDRESS_141439] Operating Procedure  
US [LOCATION_002]  
 
 
Study number:    Page 1 
Version:    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_141440]  to determine clinical 
characteristics associated with cardiac structure a nd function and in -
hospi[INVESTIGATOR_125739] . A subset of patients with history of diabetes mellitus 
and/or acute hyperglycemia (any glucose measurement >200 mg/dl) 
and evidence of acute or chronic  heart disease will be treated  in an 
open -label fashion to receive an investigational aldose reductase 
inhibitor,  AT-[ADDRESS_141441] of care. The primary objective  of the 
interventional study is provide emergency access to open -label 
treatment to COVID -19 patients with acute cardiopulmonary 
symptoms .  
Phase  Phase II  
Objectives  • To characterize serial measures cardiac structure and function  and 
in-hospi[INVESTIGATOR_125740] -19 infection  
• To develop predictive models of cardiac risk in hospi[INVESTIGATOR_60992] -
19 infection patients  
• To assess safety of  treatment with AT-[ADDRESS_141442] of care on 
in-hospi[INVESTIGATOR_125741] -19 
• To characterize the effects of treatment with AT-[ADDRESS_141443] of 
care on  in-hospi[INVESTIGATOR_34380], progression of acute lung injury 
requiring mechanical ventil ation, and serial measures of  cardiac 
structure and function  
 
Methodology  Prospective, open -label  registry with embedded  open -label study  
Study number:  s20-[ZIP_CODE]   Page 2 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Endpoint  Primary Endpoint  for Registry Study : Proportion  of subjects  with 
decreased left ventricular ejection fraction ≥10% from baseline at time 
of hospi[INVESTIGATOR_125742]: Safety of AT -001 
 
Secondary Endpoints  (for registry and clinical trial) : 
• Change in left ventricular ejection fra ction  
• Change in left ventricular end -diastolic diameter  
• Change in left ventricular end -systolic diameter  
• Change in biomarkers of cardiac injury  
• Frequency of atrial fibrillation  
• Frequency of heart block  
• Frequency of non -sustained ventricular tachycardia  
• Frequency of sustained ventricular tachycardia  
• Frequency of ventricular fibrillation  
 
Secondary Endpoints (for clinical trial):  
• Proportion  of subjects  requiring mechanical ventilation  
• Proportion  of subjects  with decrease in left ventricular ejection 
fraction ≥10%  from baseline at time of hospi[INVESTIGATOR_125743] 30 days  after  hospi[INVESTIGATOR_125744]  1-14 days per treatment physician discretion  
Population  All subjects hospi[INVESTIGATOR_21391] -19 infection hospi[INVESTIGATOR_125745]; a subgroup meeting specific entry criteria 
listed below will be enrolled in the open -label interventional trial 
Study Sites  NYU Langone Tisch Hospi[INVESTIGATOR_307]  (registry and embedded clinical trial)  
NYU Langone Brooklyn Hospi[INVESTIGATOR_307]  (registry only)  
NYU Langone Winthrop Hospi[INVESTIGATOR_307]  (registry and embedded clinical 
trial) 
Bellevue Hospi[INVESTIGATOR_54246] (registry only)  
Number of 
participants  500 registry subjects enrolled at all sites  
20 interventional trial subjects at NYU Tisch Hospi[INVESTIGATOR_125746]/Procedure  AT-001 is an investigational novel Aldose Reductase Inhibitor (ARI) in 
Phase 2/3 development in the US, Canada and Europe for treatment of 
Diabetic Cardiomyopathy.  The US IND# is 136043. A full 
Investigational Brochure is for the ongoing Diabetic Cardiomyopathy 
program  is attached to this protocol . 
Reference Therapy  Standard of care 
Key Procedures  Data extraction from electronic medical record  
Administration of AT -001 1500 mg twice daily for up to 14 days  
Study number:  s20-[ZIP_CODE]   Page 3 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Statistical Analysis  Registry Study  
 
• Multivariable logistic regression models  and Cox Proportional Hazard 
models will be used to estimate  the association between  clinical 
variables at time of hospi[INVESTIGATOR_125747] 
≥10% and secondary endpoints c ardiac structure and function.  
 
• Multivariable mixed models will be used to estimate  the association 
between serial measures of  cardiac structure and function  and in -
hospi[INVESTIGATOR_34380].  
 
Interv entional  Study  
 
• Safety assessment of AT -001 based on reported ad verse events  
• Exploratory analyses with descriptive statistics to describe clinical 
outcomes in patients treated with AT -[ADDRESS_141444] of care  
 
 
  
Study number:  s20-[ZIP_CODE]   Page 4 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  Schematic of Study Design  
 
 
 
 
  
Hospi[INVESTIGATOR_125748]-19 infection
Clinical Data Collection For 30 
Days or Until Hospi[INVESTIGATOR_125749], Study Drug 
Administration
Clinical and Safety Data 
Collection for up to 30 Days After 
Hospi[INVESTIGATOR_125750]:  s20-[ZIP_CODE]   Page 5 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  1 Key Roles  
 
Name  [CONTACT_125786]  [INVESTIGATOR_125751]-Investigator  NYU Grossman 
SOM  Department of 
Medicine  NYU Tisch  
Harmony 
Reynolds  Co-Investigator  NYU Grossman 
SOM  Department of 
Medicine  NYU Tisch  
Glenn Fishman  Co-Investigator  NYU Grossman 
SOM  Department of 
Medicine  NYU Tisch  
Alex 
Reyentovich  Co-Investigator  NYU Grossman 
SOM  Department of 
Medicine  NYU Tisch  
Claudia Gidea  Co-Investigator  NYU Grossman 
SOM  Department of 
Medicine  NYU Tisch  
Juan Gaztanaga  Co-Investigator  NYU Grossman 
SOM  Department of 
Medicine  NYU 
Winthrop  
 
2 Background Information and Scientific Rationale  
2.1 Background  Informatio n and Relevant Literature  
An outbreak of viral pneumonia in Hubei province China in December 2019 led to the 
identification of a novel coronavirus ( SARS -CoV -2, subsequently renamed as COVID -19) as the 
etiologic agent .1, [ADDRESS_141445] cells via interaction with membrane -bound 
angiotensin converting enzyme -isoform 2 (ACE2) on respi[INVESTIGATOR_125752]. ACE2 is part of the 
renin -angiotensin -aldosterone (RAAS) neurohormonal pathway , a neuroendocrine, paracrine, 
and autocrine system that regulates cardiac structure and function, vasomotor tone, sodium 
metabolism, and blood pressure homeostasis . COVID -19 infection is also associated with 
activation of inflammatory cytokines that induce myocardial contractile dysfunction, myocyte 
cell injury, cardiac arrhythmias, and vascular endothelial cell and smooth cell dysfunction.  
Initial reports from China  in 41 patients  indicated that severe COVID -19 infection in 
hospi[INVESTIGATOR_125753] 10 -20% risk of cardiac complications 
includ e increased biomarkers of myocardial injury, decreased left ventricular contractile 
function, cardiac arrhythmias, chest pain, hypotension, and fatal circulatory collapse.[ADDRESS_141446] occurring in young patients recovering 
from  COVID -19 induced acute respi[INVESTIGATOR_1399].  
The current study is being undertaken to create increase knowledge of the cardiovascular 
complications of COVID -19 infection at NYU Langone Health and Bellevue Hospi[INVESTIGATOR_54246]. A 
prospective registry is proposed  to characterize the cardiovascular manifestations of COVID -19 
Study number:  s20-[ZIP_CODE]   Page 6 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  infection in US patients. The prospective registry also provides a platform for execution of a 
clinical trial of an investigational agent for treatment of COVID -19 infection.  
Aldose reductase ( AR), the first and rate -limiting step in the polyol pathway, is activated by 
[CONTACT_125771]. AR initiates this pathway by [CONTACT_125772] -
dependent reduction of the aldehyde form of glucose to produce sorbitol as an intermediate . 
Sorbitol is then oxidized using NAD to form fructose, catalyzed by [CONTACT_125773]. Excess intracellular sorbitol produced by [CONTACT_125774], resulting in 
osmotic damage and ultimately cell death  (figure 1).4, 5 
 
 
 
Aldose Reductase plays a critical role in mediation of oxidative tissue damage  in setting of 
inflammation induced by [CONTACT_125775].6 A potent Aldose Reductase Inhibitor (ARI) with 
a favorable safety profile may be an important tool for short -term use in the  clinical setting to 
prevent lung inflammatory damage and cardiomyopathy in patients with  COVID -19 infection.7, 8 
 
Aldose Reductase Inhibitors (ARIs), including the first -generation ARI zopolrestat , and the next 
generation ARI, AT -001 prevent oxidative -induced cardiac and lung injury  in vivo and in vitro 
by [CONTACT_125776] -induced downstream accumulation  of reactive oxygen species  and advanced 
glycation end -products . AT-001 has been shown to prevent o xidative damage to cardiomyocytes 
in oxidative -induced cardiomyopathies. AT -001 prevents ischemic/oxidative damage to 
cardiomyocytes in an ex -vivo system and decreases CK and other markers of cardiac damage In 
a Phase 1/2 clinical trial, AT -001 treatment i n patients with Diabetic Cardiomyopathy decreased 
NTproBNP levels, a biomarker  of cardiac stress or damage.  
 
AT-001 demonstrates approximately 1,000 -fold increased activity or potency vs. prior ARIs with 
excellent safety and tolerability profile . (see atta ch Investigator Brochure and Reference : Perfetti 
et al Overcoming the Safety Challenges of Aldose Reductase Inhibition: Development of AT -
001 for Diabetic Cardiomyopathy; poster presented at WCIR Dec 2019; 
https://www.appliedtherapeutics.com/wp -
content/uploads/2020/01/2019_WCIRDC_Poster_Final_1.pdf ) 
 

Study number:  s20-[ZIP_CODE]   Page 7 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  This interventional trial  is intended to allow open -label emergency use of AT -001 for COVID -19 
infec ted patients experiencing acute cardiopulmonary sequelae of disease.  
2.2 Name [CONTACT_125787]-001 is a small molecule with a molecular weight of 421 g/mol. Its chemical structure is 
provided below.  
 
Chemical Structure of AT-[ADDRESS_141447] is provided as AT -001 powder in a capsule in a 500 mg strength, packaged 
in blister cards.  There are no excipi[INVESTIGATOR_125754] -001 powder in capsule, 
and no materials of human or animal origin are present. Th e white, opaque capsule shells contain 
hypromellose and titanium dioxide.  AT-001 is currently in Phase 2/3 development for Diabetic 
Cardiomyopathy under IND 136043.  Based on pre -clinical and clinical data presented in the 
Investigator Brochure, a dose of 1 ,500mg BID (3 X 500mg capsules twice daily) will be used . 
 
AT-001 is an inhibitor of aldose reductase (AR), the first and rate -controlling enzyme of the 
polyol pathway which converts glucose to sorbitol and then to fructose. Hyperactivation of this 
pathway in patients with diabetes is thought to play a critical role in the pathogenesis of diabetic 
complications, including damage to peripheral nerves and blood vessels. Excess intracellular 
sorbitol produced by [CONTACT_125774], resulting in osm otic damage and ultimately cell 
death (Miki 2013). This pathological effect of excess sorbitol in cardiac cells can be seen in 
ventricular myocardial biopsies from diabetic patients which show significantly higher necrotic 
cardiomyocytes compared to biopsi es from non -diabetic patients (Frustaci 2000).  
 
In vitro assays demonstrate that AT -001 binds to AR with high affinity and specificity, and with 
no evidence of off -target effects. In in vivo animal studies, AT -001 normalized sorbitol levels in 
diabetic rat s, prevented cardiac ischemic injury in diabetic mice, prevented acute cardiac 
ischemic injury in non -diabetic rats, and treated acute cardiac ischemic injury in non - diabetic 
rats. 
2.2.1  Preclinical Data  
A comprehensive program to evaluate the preclinical profi le of AT -001 has been conducted to 
support the clinical development program . In vivo Good Laboratory Practice ( GLP ) safety 
pharmacology studies showed no effect of AT -001 on gross behavioral, physiological, or 
neurological function in rats (Irwin Test), an d no cardiovascular or respi[INVESTIGATOR_125755] 2000 mg/kg/day, the highest dose studied.  The AT -001 oral toxicology program to 
date consists of two single -dose studies in rats, one single -dose study in dogs, a dose range 
finding study in  rats, a dose range finding study in dogs, two definitive 28 -day GLP studies (rats, 
dogs); and two chronic GLP toxicity studies conducted in rats (26 weeks) and dogs (39 weeks). 
In vitro and in vivo genotoxicity testing has been performed. Doses up to 2000  mg/kg/day have 

Study number:  s20-[ZIP_CODE]   Page 8 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  been orally administered to rats and dogs for up to 39 weeks.  In the single -dose studies, the MTD 
was considered to be 2000 mg/kg/day, since there were no findings in these studies. In the [ADDRESS_141448] le vel (NOAEL ) was determined to be 2000 
mg/kg/day in both rats and dogs.  Four reproductive studies of the effects of AT -[ADDRESS_141449] been 
conducted: 2 studies in rats (GLP) and 2 studies in rabbits (one non -GLP, one GLP).  Based on 
these findings, the NOAEL for m aternal and embryo/fetal developmental toxicity was 1000 
mg/kg/day (the highest dosage level tested) in rats and 200 mg/kg/day in rabbits . AT-001 was 
shown to be negative for mutagenic activity in the reverse mutation assay, negative in the in vitro 
micron ucleus assay, and negative in the in vivo micronucleus assay.  
2.2.2  Clinical Data to Date  
To date, one clinical study (AT -001.1001) has been conducted with AT -001. Full details are 
provided in the attached Investigator Brochure.  
 
StudyAT -001-1001, the first in h uman study of AT -001, was a Phase 1 -2, three -part, 
randomized, placebo -controlled study designed to assess the safety, tolerability, PK, and PD 
(effect on sorbitol) of AT -001 in adults with Type 2 Diabetes Mellitus ( T2DM ). Since AR 
converts glucose to sorb itol, and AR activity is elevated in diabetic patients, sorbitol 
normalization was examined as a PD biomarker of target engagement. The study had 3 parts: 
single ascending dose ( SAD ) (Part A), 7 -day multiple ascending dose ( MAD ) (Part B), and a 28 -
day MAD extension part (Part C). A thorough safety review of each dose cohort was conducted 
prior to escalation to the next higher dose.  
 
All doses and dosing regimens were well -tolerated with no safety issues identified. There were 
no serious adverse events (SAEs ) considered treatment -related and no AEs causing 
discontinuation of study treatment. No clinically relevant changes in vital signs, ECG or clinical 
safety laboratory values were noted. AT -[ADDRESS_141450] been conducted with AT -001 to date.  The potential of 
AT-001 to inhibit the catalytic activities of key CYP isoforms was evaluated in an in vitro 
metabolism study using recombinant human CYP isoforms, while its potential to induce the 
catalytic activities of key CYP isoforms was evaluated in an ex vivo metabolism study using 
human hepatocytes.  AT-001 over the concentration range tested (0.[ZIP_CODE] to 50.0 μM) did not 
signifi cantly inhibit human CYP450 isozymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4 
(midazolam and testosterone substrates). The induction of human CYP1A2, 2B6, and 3A4 by 
[CONTACT_50182]-[ADDRESS_141451] concentration tested (100 μM), observed in one of the three lots of 
hepatocytes, was lower than that with the control inducers which produced effects in all lots of 
hepatocytes.  
Study number:  s20-[ZIP_CODE]   Page 9 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  2.2.3  Dose Rationale (if applicable)  
The [ADDRESS_141452] high 
mortality rates, primarily attributable to respi[INVESTIGATOR_1444] a substantial minority with 
cardiovascular complications. The proposed study will provid e novel data in US patients to 
enhance cardiovascular risk prediction and identify potential novel therapi[INVESTIGATOR_125756].  
 
2.4 Potential  Risks & Benefits  
2.4.[ADDRESS_141453] in human study (Stu dy AT -001.1001) AT -001 was generally well 
tolerated with no safety issues identified. There were no SAEs considered treatment -related and 
no AEs causing discontinuation of study treatment. No clinically relevant changes in vital signs, 
ECG or clinical safe ty laboratory values were noted.  
 
Potential risks of AT -001 based on non-clinical data and previous experience with other aldose 
reductase inhibitors include:  
 
• Acute hypersensitivity reactions  
• Hepatic toxicity, including fatal hepatic necrosis  
• Renal toxici ty: Nephrolithiasis (calculi and pelvic dilation suggestive of an obstructive mechanism 
leading to development of pyelonephritis were reported in female rats in a 6 -month chronic 
toxicology study. These renal findings were not reproduced in dogs in a 9 -month chronic 
toxicology study)  
• Gastrointestinal events, including nausea, vomiting, diarrhea, flatulence, abdominal pain  
• Ocular effects (two cases of non -adverse, reversible multifocal pi[INVESTIGATOR_125757] a 28 -
day toxicology study in dogs, which wa s not reproduced in a 9 - month chronic toxicology study)  
• Hypotension and dizziness  
• Skin rash/eczema  
• Decreases in hemoglobin, erythrocyte count, and lymphocyte count  
• Reduction in total protein in blood  
 
The incidence of these side effects for short -term exp osure to AT -001 in COVID -19 patients  is 
unknown.  We anticipate that patients with COVID -19 infection will receive concomitant 
treatments including off -label use of FDA -approved drugs, anti -viral therapy with remdesivir 
under expanded access or emergency us e access, and treatment with hydroxychloroquine, 
convalescent sera, and/or IL -6 inhibitors within the context of clinical trials. Based on 
knowledge of the pathophysiology of COVID -19 infection and the pharmacology of AT -001, we 
do not anticipate that thes e concomitant medications will increase risk associated with AT -001. 
Patients with COVID -19 infection are known to be a high risk of complications including 
Study number:  s20-[ZIP_CODE]   Page 10 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  multisystem organ failure (liver, kidney, heart, lung, hematological system, nervous system with 
associated laboratory abnormalities) and septic shock (hypotension with metabolic 
abnormalities).  We will collect daily clinical information to monitor evidence of organ 
dysfunction and septic shock in the electronic CRF. We will identify potential AE relate d to 
study drug based upon temporal relationship with study drug administration, AE in the above list 
of potential AE associated with aldose reductase inhibition, or suspi[INVESTIGATOR_125758]/or duration of organ dysfunction and associated laborator y abnormalities is different from 
that expected due to COVID -[ADDRESS_141454] in human study, there is  
possible benefit to subjects who receive AT -001 in the interventional study.  
 
 
3 Objectives and Purpose  
3.1 Primary Objective  
• Registry Study: To characterize serial measures cardiac structure and function and in -hospi[INVESTIGATOR_125759] -19 infection  
• Interventional Trial: To characterize safety of AT -001 in hospi[INVESTIGATOR_41374] -19 
infection  
3.2 Secondary Objectives (if applicable)  
• To develop predictive models of cardiac risk in hospi[INVESTIGATOR_60992] -19 infection patients  
• To assess safety of treatm ent with AT -[ADDRESS_141455] of care on in -hospi[INVESTIGATOR_125760] -19 
• To characterize the effects of treatment with AT -[ADDRESS_141456] of care on in -hospi[INVESTIGATOR_34380], 
progression of acute lung injury requiring mechanical ventilation, and serial measures of cardiac 
structure and function  
4 Study  Design  and Endpoints  
4.1 Description of Study Design  
The proposed study is a prospective registry of patients hospi[INVESTIGATOR_21391] -19 infections 
at participating sites (NYU Tisch, NYU Brooklyn, NYU  Winthrop, Bellevue Hospi[INVESTIGATOR_54246]). 
Clinical data related to the COVID -[ADDRESS_141457]  as described below in patients who meet study entry criteria . To maintain confidentiality, 
all subjects will be assig ned a unique study identifier number. De -identified data will be recorded 
in an electronic database (REDCap).  
 
A subset of patients enrolled in the registry study may be eligible to participate in a n open -label 
interventional trial of AT-001. For the subst udy, informed consent will be obtained at the time of 
study entry, and clinical data will be extracted from the medical record using the same protocol 
Study number:  s20-[ZIP_CODE]   Page 11 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  as the registry study. Additional safety and tolerability data will be collected for patients 
participati ng in the interventional trial.   
 
4.2 Study Endpoints  
4.2.1  Primary Study Endpoints  
 
Primary Endpoint for Registry Study: Proportion of subjects with decreased left ventricular 
ejection fraction ≥10% from baseline at time of hospi[INVESTIGATOR_125742]: Safety of AT -001 based on adverse events 
reporting  
 
4.2.2  Secondary Endpoints  
 
Secondary Endpoints (for registry and clinical trial):  
• Change in left ventricular ejection fraction  
• Change in left ventricular end -diasto lic diameter  
• Change in left ventricular end -systolic diameter  
• Change in biomarkers of cardiac injury  
• Frequency of atrial fibrillation  
• Frequency of heart block  
• Frequency of non -sustained ventricular tachycardia  
• Frequency of sustained ventricular tachycardia  
• Frequency of ventricular fibrillation  
 
Secondary Endpoints (for clinical trial):  
• Proportion of subjects requiring mechanical ventilation  
• Proportion of subjects with decrease in left ventricular ejection fraction ≥10% from baseline at 
time of hospi[INVESTIGATOR_28689] 
 
5 Study Enrollment  and Withdrawal  
5.1 Inclusion Criteria  
Registry Study: In order to be eligible to participate in the registry  study, an individual must 
meet all of the following criteria:  
1. Age ≥18 years of age  
2. Hospi[INVESTIGATOR_125761]  
3. Confirmed COVID -19 infection  
 
Interventional Study: In order to be eligible to participate in the registry study, and individual must meet all 
of the inclusion criteria of the registry study plus the  following critieria:  
 
1. Hospi[INVESTIGATOR_125762]  
2. History of diabetes mellitus or blood glucose measurement >126 mg/dl  
AND   
EITHER  
Study number:  s20-[ZIP_CODE]   Page 12 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  3. History of hypertension and/or ischemic heart disease  and/or heart failure  
OR 
4. Other co -morbid condition that in the opi[INVESTIGATOR_125763]  
 
5.2 Exclusion Criteria  
Registry Study: An individual who meets any of the following criteria will be excluded from 
participation in the regi stry study:  
1. Persons who have opted out of research participation at NYU  
2. Pregnancy  
 
 
Interventional study: An individual who meets any of the following criteria will be excluded 
from participation in the interventional  study:  
1. Persons who have opted out of r esearch participation at NYU  
2. Pregnancy  
3. Women of childbearing potential  
4. Breast -feeding women  
5. Participation in another  FDA-regulated  investigational drug placebo -controlled clinical trial within 
previous 30 days  
6. Hospi[INVESTIGATOR_125764] >14 days  
7. Inability to comply with oral or nasogastric tube administration of study drug  
 
Co-enrollment in other interventional studies in the COVID -19 population will be permitted if in 
the judgement of the PI [INVESTIGATOR_80336], the re is no anticipated inc rease in risk of exposure to AT -
001 based on the known pathophysiology of COVID -19 infection and pharmacology of AT -001, 
and co -enrollment is permitted in the other protocol(s) . Co-enrollment will be tracked at reported 
to the IRB and Sponsor.  
5.[ADDRESS_141458] the prospective chart review for the registry component of the study. 
Although we will need access to the subjects’ medical record for the duration of the study, an 
individual’s PHI will be destroyed once  they complete the study.  
 
The primary treatment team, which consists of critical care physicians will determine subject 
capacity based on their interactions with the patient, presence of neurological complications, and 
use of sedative agents. These critic al care physicians are qualified to assess capacity for consent 
as part of their clinical management of the patient. S ubjects will be regularly assessed  by [CONTACT_125777] . If subjects who have the capacity to consent at the onset of the 
study lose capacity during the study, their legally authorized representative will be identified and 
consent sought for the subject's continued participation in the study . If subjects regain the 
capacity to consent during the study and decline to continue participation, state they will be 
asked if previously collected data can still be used. If they decline, this data will be discarded.  
Study number:  s20-[ZIP_CODE]   Page 13 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019   
If the po tential participant lacks capacity, the legally authorized representative (identified in 
accordance with NYS as the highest in priority of the following: court appointed LAR, health 
care proxy, spouse or domestic partner, adult son or daughter, parent, gra ndparent, adult 
grandchild who maintains regular contact [CONTACT_125778]’s activities, 
health, or beliefs) will provide consent for the interventional study.  
 
5.[ADDRESS_141459] in 
charge of patient care.  The primary treatment team of critical care physicians will approach the 
patient and/or LAR regarding interest in participation in the study.  
 
5.4.1  Use of DataCore/Epic Information for Recruitment Purposes  
 
The study will use DataCore and EPIC for recruitment purposes. All subjects with COVID -[ADDRESS_141460]. An 
investigator may terminate participation in the study if:  
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued particip ation in the study would not be in the best interest of the 
participant  
Study number:  s20-[ZIP_CODE]   Page 14 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  • The participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation  
 
5.7.[ADDRESS_141461] will remain unch anged.  
 
5.8 Premature Termination or Suspension of Study  
 
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause. Written notification, documenting the reason for study suspension or 
termination, will be provi ded by [CONTACT_87077], IND/IDE 
sponsor and regulatory authorities. If the study is prematurely terminated or suspended, the PI 
[INVESTIGATOR_33894](s) for the termination or suspensio n. 
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination of futility  
• Sponsor determi nation  
 
Study may resume once concerns about safety, protocol compliance, data quality are addressed 
and satisfy the spons or, IRB and/or FDA.  
 
6 Study Agent  (Study drug, device, biologic, vaccine  etc.) and/or 
Procedural Intervention   
6.1 Study Agent(s) Description  
Product: AT -001 500mg capsule for oral administration  
Dosage: 1,500mg (3X500mg capsules) twice daily  
Mode of Administration: Oral  
Compound:  
 
 
Please see attached Sponsor pharmacy manual for additional details.  
6.1.[ADDRESS_141462] will be shipped  by [CONTACT_125779]:  s20-[ZIP_CODE]   Page 15 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_141463] is stable at room temperature  
 
6.1.4  Preparation  
None  
 
6.1.5  Dosing and Administration  
Three 500 mg capsules (1500 mg) twice daily  
 
6.1.[ADDRESS_141464]  
 
7 Study Procedures  and Schedu le 
7.1 Study Procedures/Evaluations  
7.1.[ADDRESS_141465]. The data collection 
will be performed by [CONTACT_125780], and will be recorded on de -
identifie d electronic case report forms (see Appendix for eCRF).  
 
Study number:  s20-[ZIP_CODE]   Page 16 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_141466] of care for COVID -19 infection. This includes supportive 
measures for symptomatic relief, assisted ventilation including use of sedatives, pharmacological 
management of shock, organ injury, co -morbid bacterial infections, and co -morbid conditions.  
 
7.2 Laboratory Procedures/Evaluations  
7.2.[ADDRESS_141467] of care laboratory procedures will be perfo rmed ; results will be recorded in the research 
database  There are no study -related laboratory evaluations.  
 
• Hematology:  hemoglobin, hematocrit, white blood cells (WBC) with differential count, platelet 
count.  
• Biochemistry:  serum electrolytes, blood urine n itrogen, creatinine, total bilirubin, alanine 
aminotransferase (ALT), aspartate  aminotransferase (AST) , albumin, total protein, calcium, 
magnesium, phosphate,  troponin -I, brain natriuretic peptide, ferritin, CRP, ESR, IL -6, . 
• Urinalysis:  dipstick urinalysis, including protein, hemoglobin and glucose; if dipstick is abnormal, 
complete urinalysis with microscopic evaluation is required.  
• Pregnancy test , usually to  be done within [ADDRESS_141468].  
 
7.3 Study Schedule  
Registry Study: All clinically -derived data on the attached eCRF will be collected on a daily 
basis  until hospi[INVESTIGATOR_2345], or first 30 days of hospi[INVESTIGATOR_059] (whichever is shorter).  
 
Interventional study: All clinically -derived data on the attached eCRF will be collected on a daily 
basis  during IP administration, with safety monitoring continuing [ADDRESS_141469]  dose of IP. In 
additional the following study procedures will be performed:  
 
7.3.1  Enrollment/ Baseline  
Enrollment/Baseline Visit (Visit 1, Day 0)  
• Obtain informed consent for potential participant (or their LAR) verified by [CONTACT_125781].  
• Verify inclusion/exclusion criteria.  
• See electronic case report form. These data will be collected at baseline.  
• Start study drug administration  
• Safety monitoring  
 
7.3.2  Daily Interventional Study Visits (up to 14 days)  
• See electronic case report fo rm. These data will be collected daily.  
• Study drug administration  
• Safety monitoring  
 
Study number:  s20-[ZIP_CODE]   Page 17 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  7.3.3  Final Study Visit  
• Safety monitoring for [ADDRESS_141470] dose of IP  
 
7.3.4  Withdrawal /Early Termination Visit  
See electronic case report form  
 
7.4 Concomitant Medications, Treatments, and Procedures  
 
All concomitant prescription medications taken during study participation will be recorded on 
the case report forms (CRFs). For this protocol, a prescription medication is defined as a 
medication that can be prescri bed only by a properly authorized/licensed clinician. Medications 
to be reported in the CRF are concomitant prescription medications, over -the-counter 
medications and non -prescription medications.  
 
7.4.1  Precautionary Medications, Treatments, and Procedures  
None  
 
7.5 Prohibited Medications, Treatments, and Procedures  
Other investigational medications  
7.6 Prophylactic Medications, Treatments, and Procedures  
None  
 
7.7 Rescue Medications, Treatments, and Procedures  
None  
 
7.8 Participant Access to Study Agent at Study Closure  
None 
 
8 Assessment of Safety  
8.1 Specification of Safety Parameters   
All subjects in the interventional study will be observed daily by [CONTACT_125782].  
 
8.1.1  Definition of Adverse Events (AE)  
 
Study number:  s20-[ZIP_CODE]   Page 18 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  An adverse event  (AE) is any symptom, si gn, illness or experience that develops or worsens in 
severity during the course of the study.  Intercurrent illnesses or injuries should be regarded as 
adverse events.  Abnormal results of diagnostic procedures are considered to be adverse events if 
the a bnormality:  
• results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests  
• is considered by [CONTACT_1372]  
 
 
8.1.2  Definition  of Serious Adverse Events (SAE)  
 
Serious Adverse Event  
Adverse events are classified as serious or non -serious.  A serious adverse event  is any AE that 
is:  
• fatal 
• life-threatening  
• requires or prolongs hospi[INVESTIGATOR_4408]  
• results in pers istent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
 
Important medical events are those that may not be immediately life threatening, but are clearly 
of major clinical significance. They may jeopar dize the subject, and may require intervention to 
prevent one of the other serious outcomes noted above. For example, drug overdose or abuse, a 
seizure that did not result in in -patient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in 
an emergenc y department would typi[INVESTIGATOR_15355].  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non-
serious adverse events .  
 
8.1.3  Definition of Unanticipated Problems (UP)  
 
 
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in nature, severity, or frequency   (i.e. not described in study -related 
documents such as the IRB -approved protocol or consent form, the investigators brochure, 
etc) 
• Related or possibly related to participation in the research  (i.e. possibly related means 
there is a reasonable possibility th at the incident experience, or outcome may have been 
caused by [CONTACT_3459])  
Study number:  s20-[ZIP_CODE]   Page 19 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  • Suggests that the research places subjects or others at greater risk of harm  (including 
physical, psychological, economic, or social harm).  
 
8.2 Classificat ion of an Adverse Event  
8.2.1  Severity of Event  
 
For AEs not included in the protocol defined grading system, the following guidelines will be 
used to describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with func tioning.  
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or incapacitating.  
 
8.2.2  Relationship to Study Agent  
 
The clinician’s assess ment of an AE's relationship to study agent (drug, biologic, device) is part 
of the documentation process, but it is not a factor in determining what is or is not reported in 
the study. If there is any doubt as to whether a clinical observation is an AE, t he event should be 
reported. All AEs must have their relationship to study agent assessed. In a clinical trial, the 
study product must always be suspect. To help assess, the following guidelines are used.  
 
• Related – The AE is known to occur with the study agent, there is a reasonable possibility that the 
study agent caused the AE, or there is a temporal relationship between the study agent and event. 
Reasonable possibility means that there is evidence to suggest a causal relationship between the 
study agent  and the AE.  
• Not Related  – There is not a reasonable possibility that the administration of the study agent 
caused the event, there is no temporal relationship between the study agent and event onset, or 
an alternate etiology has been established.  
 
8.2.3  Expecte dness  
 
The PI  [INVESTIGATOR_118631]. An AE will 
be considered unexpected if the nature, severity, or frequency of the event is not consistent with 
the risk information previously described for the study  agent.  
 
8.3 Time Period and Frequency for Event Assessment and Follow -Up 
 
The occurrence of an AE or SAE may come to the attention of study personnel during study 
visits and interviews of a study participant presenting for medical care, or upon review by a 
study monitor. All AEs including local and systemic reactions not meeting  the criteria for SAEs 
Study number:  s20-[ZIP_CODE]   Page 20 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  will be captured on the appropriate RF. Information to be collected includes event description, 
time of onset, clinician’s assessment of severity, relationship to study product (assessed only by 
[CONTACT_8703] a diagnosis), and time of resolution/stabilization of 
the event. All AEs occurring while on study must be documented appropriately regardless of 
relationship. All AEs will be followed to adequate resolution.  
 
Any medical condition that is present a t the time that the participant is screened will be 
considered as baseline and not reported as an AE. However, if the study participant’s condition 
deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in 
the data co llection system throughout the study.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of 
the event at each level of severity to be performed. AEs characterized as intermittent require 
documentation of onset and d uration of each epi[INVESTIGATOR_1865].  
 
The PI [INVESTIGATOR_125765] 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study 
participation. At each study visit, th e investigator will inquire about the occurrence of AE/SAEs 
since the last visit. Events will be followed for outcome information until resolution or 
stabilization.   
 
All unresolved adverse events should be followed by [CONTACT_91158], the subject is lost to follow -up, or the adverse event is otherwise explained.  At the last 
scheduled visit, the investigator should instruct each subject to report any subsequent event(s) 
that the subject, or the subject’s personal physician, b elieves might reasonably be related to 
participation in this study.  The investigator should notify the study sponsor of any death or 
adverse event occurring at any time after a subject has discontinued or terminated study 
participation that may reasonably  be related to this study.  The sponsor should also be notified if 
the investigator should become aware of the development of cancer or of a congenital anomaly 
in a subsequently conceived offspring of a subject that h as participated in this study.  
 
8.4 Report ing Procedures  – Notifying the IRB  
8.4.[ADDRESS_141471].  
 
8.4.2  Serious Adverse Event Reporting  
 
According to CFR 21 CFR 312.32(c)(1), “the sponsor must notify FDA and all participating 
investigators in an IND safety report of potential serious risks, from clinical trials or any other 
source, as soon as possible, but i n no case later than [ADDRESS_141472] 
identify all IND safety reports previously submitted to FDA concerning a similar suspected 
Study number:  s20-[ZIP_CODE]   Page 21 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_141473] a causal 
relationship between the drug and the adverse event, such as:  
 
(A) A single occurrence of an event that is uncommon and known to be strongly associated wi th 
drug exposure (e.g., angioedema, hepatic injury, Stevens -Johnson Syndrome);  
(B) One or more occurrences of an event that is not commonly associated with drug exposure, 
but is otherwise uncommon in the population exposed to the drug (e.g., tendon rupture ); 
(C) An aggregate analysis of specific events observed in a clinical trial (such as known 
consequences of the underlying disease or condition under investigation or other events that 
commonly occur in the study population independent of drug therapy) tha t indicates those events 
occur more frequently in the drug treatment group than in a concurrent or historical  ̮control 
group.”  
 
Furthermore, according to 21 CFR 312 .32(̮c)(2), “the sponsor must also notify FDA of any 
unexpected f atal or life-threatening suspected adverse reaction as soon as possible but in no case 
later than 7 calendar days after the sponsor’s initial receipt of the information.”  
 
8.4.3  Unanticipated Problem Reporting  
 
Incidents or events that meet the OHRP criteria for UPs req uire the creation and completion of 
an UP report form. It is the site investigator’s responsibility to report UPs to their IRB and to the 
DCC/study sponsor. The UP report will include the following information:  
 
• Protocol identifying information: protocol t itle and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP;  
• A description of a ny changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP.  
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following 
timeline:  
 
• UPs that are SAEs will be reported to t he IRB and to the study sponsor within 24 hours of the 
investigator becoming aware of the event.  
• Any other UP will be reported to the IRB and to the study sponsor within 72 hours of the 
investigator becoming aware of the problem.  
• All UPs should be reported  to appropriate institutional officials (as required by [CONTACT_17347]’s 
written reporting procedures)  within  72 hours of the IR’s receipt of the report of the problem from 
the investigator.  
 
8.4.4  Reporting of P regnancy  
Pregnancy will be considered an unanticip ated event and will be reported to the IRB and Sponsor 
within 24 hours.  
Study number:  s20-[ZIP_CODE]   Page 22 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  8.5 Reporting Procedures – Notifying the Study Sponsor  
 
The study clinician will complete a SAE Form within the following timelines:  
 
• All deaths and immediately life -threatening events, whether related or unrelated, will be recorded 
on the SAE Form and submitted to the DCC/study sponsor within [ADDRESS_141474] information.  
• Other SAEs regard less of relationship will be submitted to the DCC/study sponsor within 72 hours 
of site awareness.  
 
All SAEs will be followed until satisfactory resolution or until the site investigator deems the 
event to be chronic or the adherence to be stable. Other su pporting documentation of the event 
may be requested by [CONTACT_15791]/study sponsor and should be provided as soon as possible.  
 
As a follow -up to the initial report, w ithin the following [ADDRESS_141475] the 
understanding of the event.  Significant new information on ongo ing unanticipated adverse  
effects shall be provided promptly to the study sponsor.  
 
8.6 Study Halting Rules  
 
Administration of study agent will be halted when th ree grade 3 AEs determined to be “probably 
related” are reported to the Sponsor .  
 
8.7 Safety Oversight  
 
It is the responsibility of the Principal Investigator  [INVESTIGATOR_125766]/her site.  This safety monitoring will include  careful assessment and appropriate reporting 
of adverse events as noted above, as well as the construction and implementation of a site data 
and safety -monitoring plan . The data safety monitoring plan will consist of daily review of the 
clinical and labor atory data recorded in the attached electronic CRF. Medical monitoring will 
include a regular assessment of the number and type of serious adverse events  with complete 
review of the clinical course of each subject after 7 and 14 days of treatment . Due to t he nature 
of COVID -19 infection, many events related to organ dysfunction and septic shock are 
anticipated in this population. Only suspected treatment related adverse events, based on 
temporal relationship, biological plausibility of relation to aldose re ductase inhibition, or 
magnitude/duration greater than anticipated from COVID -[ADDRESS_141476] safety.  
 
Study number:  s20-[ZIP_CODE]   Page 23 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_141477] o f the trial is in compliance with the currently approved protocol/amendment(s), with 
GCP, and with applicable regulatory requirement(s).  
 
• The PI  [INVESTIGATOR_125767].  
• Independent audits will not be conducted to ensure monitoring practices are performed 
consistently across all participating sites.  
• Each clinical site will perform internal quality management of study conduct, data collection, 
documentation and completion. An individualized quality manag ement plan will be developed to 
describe a site’s quality management.  
 
10 Statistical Considerations  
10.1 Statistical and Analytical Plans  (SAP)  
Due to the urgent COVID -[ADDRESS_141478] one dose of AT -001 
 
10.4 Description of Statistical Methods  
10.4.1  General A pproach  
Descriptive statistics will be used to define data missingness, data distributions.  
 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  
Registry Study  
 
Study number:  s20-[ZIP_CODE]   Page 24 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  • Multivariable logistic regression models and Cox Proportional Hazard models will be used to 
estimate the association between clinical variables at time of hospi[INVESTIGATOR_125768] ≥10% and 
secondary endpoints cardiac structure and function.  
 
• Multivariable mi xed models will be used to estimate the association between serial measures of 
cardiac structure and function , need for mechanical ventilation,  and in -hospi[INVESTIGATOR_34380].  
 
Interventional Study  
 
• Safety assessment of AT -001 based on reported adverse events  
• Exploratory analyses with descriptive statistics to estimate effects of co -enrollment on safety 
outcomes  
• Exploratory analyses with descriptive statistics to describe clinical outcomes in patients treated  
10.4.3  Analysis of the Secondary Endpoint(s)  
The same analys es will be used for secondary endpoints.  
10.4.4  Safety Analyses  
Adverse events will be analyzed as summary statistics and coded by [CONTACT_61132].  
 
10.4.5  Adherence and Retention Analyses  
Data missingness will be assessed with descriptive statistics.  
 
10.4.6  Baseline Descriptive Stati stics  
Baseline characteristics will be summarized with non -parametric statistics  
 
10.5 Sample Size  
The estimated sample size for the registry (500 participants) and the interventional trial (20 
participants) are convenience samples based on the anticipated number of patients at NYU with 
COVID -[ADDRESS_141479] the regression 
analyses for the registry (up to 50 predictor variables), and for safety assessment of AT -001. 
11 Source Documents and Access to Source Data/Documents  
 
Source data is all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source 
data are contained in source  documents.  Examples of these original documents, and data records 
include: hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_10379], 
microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and 
records kept at the pharmacy, at the laboratories, and at medico -technical departments involved 
in the clinical trial.  It is acceptable to use CRFs as source documents. If this is the case, it should 
Study number:  s20-[ZIP_CODE]   Page 25 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  be stated in this section what data will be collected on CRFs and what data will be collected from 
other sources.  
 
The stu dy case report form (CRF) is the primary data collection instrument for the study.  All 
data requested on the CRF must be recorded.  All missing data must be explained.  If a space on 
the CRF is left blank because the procedure was not done or the question  was not asked, write 
“N/D”.  If the item is not applicable to the individual case, write “N/A”.  All entries should be 
printed legibly in black ink.  If any entry error has been made, to correct such an error, draw a 
single straight line through the incor rect entry and enter the correct data above it.  All such 
changes must be initialed and dated.  DO NOT ERASE OR WHITE OUT ERRORS.  For 
clarification of illegible or uncertain entries, print the clarification above the item, then initial and 
date it.  
 
Acces s to study records will be limited to IRB -approved members of the study team. The 
investigator will permit study -related monitoring, audits, and inspections by [CONTACT_1201]/EC , the 
sponsor, government regulatory bodies, and University compliance and quality ass urance groups 
of all study related documents (e.g. source documents, regulatory documents, data collection 
instruments, study data etc.).  The investigator will ensure the capability for inspections of 
applicable study -related facilities (e.g. pharmacy, di agnostic laboratory, etc.).  
 
Participation as an investigator in this study implies acceptance of potential inspection by 
[CONTACT_16478].  
 
12 Quality Assurance and Quality C ontrol  
 
QC procedures will be implemented beginning with the data entry system and data QC checks 
that will be run on the database will be generated. Any missing data or data anomalies will be 
communicated to the site(s) for clarification/resolution.  
 
Following written SOPs, the monitors will verify that the clinical trial is conducted and data are 
generated, documented (recorded), and reported in compliance with the protocol, GCP, and the 
applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing 
Practices (GMP)).  
 
The investigational site will provide direct access to all trial related sites, source data/documents, 
and reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_125783] y authorities.  
 
13 Ethics/Protection of Human Subjects  
13.[ADDRESS_141480]  
 
Study number:  s20-[ZIP_CODE]   Page 26 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  The investigator will ensure that this study is conducted in full conformity with Regulations for 
the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50,  21 
CFR Part 56, and/or the ICH E6.  
 
13.[ADDRESS_141481]  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the IRB for review and approval. Approval of both the protocol and the consent 
form must be obtained before any participant is enrolled. Any amendment to the protocol will 
require review and approval by [CONTACT_3484]. All 
changes to the consent form will be IRB approved; a determinati on will be made regarding 
whether previously consented participants need to be re -consented.  
 
13.3 Informed Consent Process  
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  
 
Consent forms describing in detail the study agent, study proc edures, and risks are given to the 
participant and written documentation of informed consent is required prior to starting 
intervention/administering study product.  
 
In the event that the participant is critically ill and unable to provide consent, a study team 
member may conduct the  informed consent process via telephone or video (webex) with use of 
e-consent through REDCap to obtain and document informed consent from the subject/LAR . 
 
13.3.2  Consent Procedures and Documentation  
 
Informed consent is a process th at is initiated prior to the individual’s agreeing to participate in 
the study and continues throughout the individual’s study participation. Extensive discussion of 
risks and possible benefits of participation will be provided to the participants and thei r families. 
Consent forms will be IRB -approved and the participant will be asked to read and review the 
document. The investigator will explain the research study to the participant and/or LAR and 
answer any questions that may arise. All participants will receive a verbal explanation in terms 
suited to their comprehension of the purposes, procedures, and potential risks of the study and of 
their rights as research participants. Participants will have the opportunity to carefully review the 
written consent f orm and ask questions prior to signing. The participants should have the 
opportunity to discuss the study with their surrogates or think about it prior to agreeing to 
participate. The participant will sign the informed consent document prior to any procedu res 
being done specifically for the study. The participants may withdraw consent at any time 
throughout the course of the trial. A copy of the  signed  informed consent document will be given 
to the participants for their records. The rights and welfare of t he participants will be protected 
by [CONTACT_125784].  
Study number:  s20-[ZIP_CODE]   Page 27 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_141482]’s res earch record. 
The consent process, including the name [CONTACT_21811], will be thoroughly 
documented in the subject’s research record.  Any alteration to the standard consent process (e.g. 
use of a translator, consent from a legally auth orized representative, consent document presented 
orally, etc.) and the justification for such alteration will likewise be documented .  
 
In the event that the participant is not able to provide consent due to temporary loss of capacity 
during critical illn ess, the LAR will provide consent.  
 
13.[ADDRESS_141483] of 1996 (HIPAA).  
Those regulations require a signed subject authorization informing the subject of the followi ng:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information   
• The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability to use all information collected prior to t he revocation of subject 
authorization.  For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) at 
the end of their scheduled study period.  The research record data will be securely stored on the 
NYU REDCap database with password controlled access limited to authorized study personnel. 
The research record will not contain any identifiers. Each subject will be assigned a random 
study ID  number. The link between the subject PHI and the study ID number will be maintained 
by [CONTACT_978] [INVESTIGATOR_125769] a 
locked cabinet in a locked room.  
 
[ADDRESS_141484] Keepi[INVESTIGATOR_007]  
14.1 Data Collection and Management Responsibilities  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site PI. The investigator is responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported.  
Study number:  s20-[ZIP_CODE]   Page 28 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019   
All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data. Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making 
changes or corrections, cross out the original en try with a single line, and initial and date the 
change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON 
THE ORIGINAL.  
 
Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source documents and 
maintained for recording data for each participant enrolled in the study. Data reported in the 
eCRF derived from source documents should be consistent with the source documents or the 
discrepancies should be explained and captured in a progress note and maintained in the 
participant’s official electronic study record.  
 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and 
clinical laboratory data will be entered into <specify name [CONTACT_64500]>, a 21 CFR 
Part 11 -compliant data capture system pr ovided by [CONTACT_941] <specify DCC>. The data system 
includes password protection and internal quality checks, such as automatic range checks, to 
identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered 
directly from the sou rce documents.  
 
14.2 Study Records Retention  
 
Study documents  will be retained for the longer of 3 years after close -out, 5 years after final 
reporting/publication , or [ADDRESS_141485] approval of a marketing application  is approved for 
the drug for the i ndication for which it is being investigated  or 2 years after the investigation is 
discontinu ed and FDA is notified if no application is to be filed or if the application has not been 
approved for such indication. No records will be destroyed without the w ritten consent of the 
sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these 
documents no longer need to be retained.  
 
14.3 Protocol Deviations  
 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of 
Procedures  (MOP)  requirements. The noncompliance may be either on the part of the participant, 
the investigator, or the study site staff. As a result of deviations, corrective actions are to be 
developed by [CONTACT_3483].  
 
These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 
Study number:  s20-[ZIP_CODE]   Page 29 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  It is the responsibility of the site PI/study staff to use continuous vigilance to identify and report 
deviations within [ADDRESS_141486] be reported to the local IRB per their guidelines. The site PI/study staff 
is respon sible for knowing and adhering to their IRB requirements. Further details about the 
handling of protocol deviations will be included in the MOP.  
 
14.4 Publication and Data Sharing Policy  
 
This study will comply with the NIH Public Access Policy, which ensures t hat the public has 
access to the published results of NIH funded research. It requires scientists to submit final peer -
reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central 
upon acceptance for publication.  
 
The Intern ational Committee of Medical Journal Editors (ICMJE) member journals have adopted 
a clinical trials registration policy as a condition for publication. The ICMJE defines a clinical 
trial as any research project that prospectively assigns human subjects to intervention or 
concurrent comparison or control groups to study the cause -and-effect relationship between a 
medical intervention and a health outcome. Medical interventions include drugs, surgical 
procedures, devices, behavioral treatments, process -of-care changes, and the like. Health 
outcomes include any biomedical or health -related measures obtained in patients or participants, 
including pharmacokinetic measures and adverse events. The ICMJE policy, and the Section [ADDRESS_141487] of 2007, requires that all clinical trials be 
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_38082]. Other biomedical journals are considering adopting similar 
policies. F or interventional clinical trials performed under NIH IC grants and cooperative 
agreements, it is the grantee’s responsibility to register the trial in an acceptable registry, so the 
research results may be considered for publication in ICMJE member journa ls. The ICMJE does 
not review specific studies to determine whether registration is necessary; instead, the committee 
recommends that researchers who have questions about the need to register err on the side of 
registration or consult the editorial office of the journal in which they wish to publish.  
 
FDAAA mandates that a "responsible party" (i.e., the sponsor or designated principal 
investigator) register and report results of certain "applicable clinical trials":  
 
• Trials of Drugs and Biologics: Controlle d, clinical investigations, other than Phase I investigations 
of a product subject to FDA regulation;  
• Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation 
(other than small feasibility studies) and pediatric post market surveillance studies.  
• NIH grantees must take specific steps to ensure compliance with NIH implementation of FDAAA.  
 
Study number:  s20-[ZIP_CODE]   Page 30 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_141488] that is appropriate to their participation in the trial. The 
study leadership in conjunction with the <specify NIH IC> has established policies and 
procedures for all study group members to disclose al l conflicts of interest and will establish a 
mechanism for the management of all reported dualities of interest.   
 
Any investigator who has a conflict of interest with this study (patent ownership, royalties, or 
financial gain greater than the minimum allo wable by [CONTACT_1385], etc.) must have the 
conflict reviewed by [CONTACT_33913] (CIMU)  with a 
Committee -sanctioned conflict management plan that has been reviewed and approved by [CONTACT_125785]. All NYULMC  investigators will follow the  
applicable  conflict of interest policies . 
 
  
Study number:  s20-[ZIP_CODE]   Page 31 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  18 References  
 
1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao 
Y, Li Y, Wang X and Peng Z. Clinical Characteristics of 138 Hospi[INVESTIGATOR_45077] 2019 
Novel Coronavirus -Infected Pneumonia in Wuhan, China. JAMA . 2020.  
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei 
Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H and Cao B. Clinical course and risk factors for 
mortality of adult inpatients with COVID -19 in Wuhan, China: a retrospec tive cohort study. 
Lancet . 2020.  
3. Zheng YY, Ma YT, Zhang JY and Xie X. COVID -[ADDRESS_141489] B and 
Anversa P. Myocardial cell death  in human diabetes. Circ Res . 2000;87:1123 -32. 
5. Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF, Schmidt AM and Ramasamy R. 
Aldose reductase and AGE -RAGE pathways: key players in myocardial ischemic injury. Ann N 
Y Acad Sci . 2005;1043:702 -9. 
6. Miki T, Yuda S, Kouzu H and Miura T. Diabetic cardiomyopathy: pathophysiology and 
clinical features. Heart Fail Rev . 2013;18:149 -66. 
7. Ravindranath TM, Mong PY, Ananthakrishnan R, Li Q, Quadri N, Schmidt AM, 
Ramasamy R and Wang Q. Novel role for aldose reductase in mediating acute inflammatory 
responses in the lung. J Immunol . 2009;183:8128 -37. 
8. Son NH, Ananthakrishnan R, Yu S, Khan RS, Jiang H, Ji R, Akashi H, Li Q, O'Shea K, 
Homma S, Goldberg IJ and Ramasamy R. Cardiomyocyte aldose reductase causes heart 
failure and impairs recovery from ischemia. PLoS One . 2012;7:e46549.  
 
  
Study number:  s20-[ZIP_CODE]   Page 32 
Version: 1. 4   03 MAY  2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  19 Attachments  
These documents are relevant to the protocol, but they are not considered part of the protocol.  
They are stored and modified separately. As such, modifications to these docu ments do not 
require protocol amendments.  
 
• Sponsor Investigator Brochure  
• Sponsor Emergency use IND protocol  
• Sponsor Pharmacy Manual  
• eCRF for data collection  
 
Study number:    Page 33 
Version:    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as aut horized in 
writing by [CONTACT_110810]: 11 JAN 2019  
 20 Schedule of Events  
 
 
Activity  Daily Data 
Collection  during 
hospi[INVESTIGATOR_125770] (up 
to 14 days)  
Study team procedures       
Consent   X  
eCRF completion  X X X 
Study drug/device dispensation   X X 
Safety Monitoring (until [ADDRESS_141490] 
dose of IP)   X X 
 
 